Journal: Journal of Pharmacy Research

Article Id: JPRS-P'Col-00001944
Title: Gene polymorphism of CYP2C9 in patients with ischemic heart disease and its significance in the manifestation of genoprotective properties of meldonium
Category: Pharmacology
  • Abstract
  • Audio Abstract
  • Authors
  • Pdf File
  • Citation
  • My Reference
  • Methodology
  • Abstract

    Introduction: The work was carried out in the direction of personalized medicine - an individual approach to the appointment of a metabolic corrector meldonium to patients with ischemic heart disease (IHD) on the basis of determining the genetic characteristics of patients. Research Tasks: To study of the polymorphism of the cytochrome CYP2C9*2 C430T gene in patients with IHD and to evaluate the significance of this factor in the manifestation of the genoprotective properties of meldonium in this category of patients. Methods: A study of 90 patients with IHD: Stable angina pectoris was performed. The polymerase chain reaction was used to determine the gene polymorphisms of cytochrome CYP2C9*2 C430T. By the method of DNA comets, according to the method developed by us in in vitro tests, the effect of meldonium on the DNA of blood leukocytes of patients was evaluated.Results: The presence of gene polymorphisms by the alleles CYP2C9*2 C430T was found. They revealed a more severe clinical condition of patients with pathological genes by the alleles CYP2C9*2 C430T in connection with the apparent decrease in the enzymatic activity of cytochrome. Potential genotoxicity of meldonium was revealed when it was administered to patients with normal cytochrome CYP2C9*2 C430T (CC) genotype, and to the genoprotective effect of meldonium when administered to patients with the pathological CYP2C9*2 C430T genotype (CT genotype). Conclusion: When prescribing meldonium to patients with stable angina, one should take into account, the genetic information on the individual polymorphism of the CYP2C9 gene and give preference to individuals who have the pathologic genotype of CYP2C9*2 C430T (СТ) in view of the predicted genoprotective effect of the drug.

  • Abstract Audio

    No Audio file found

  • About the authors and Affiliations

    Author(s) Name:

    Olesya V. Romaschenko1*, Eduard A. Snegin1, Nina I. Zhernakova1, Andrey A. Shaposhnikov1, Lyudmila R. Zakirova1, Vadim V. Rumbesht1, Galina A. Batischeva2

    Affiliation(s) Name:

    1 Department of  Medicine, Belgorod State National Research University, Belgorod, Russia,
    2Department of  Medicine, Voronezh State Medical University Named after N. Burdenko, Voronezh, Russia

    *Corresponding author: Olesya V. Romaschenko, Belgorod State National Research University, 85, Pobedy Street, Belgorod - 308015, Russia.

  • View Article File in pdf format.

    Article File
  • View Article Citation Here.

    0 View More
  • How to Cite my Article.

    Author:

    Olesya V. Romaschenko1*, Eduard A. Snegin1, Nina I. Zhernakova1, Andrey A. Shaposhnikov1, Lyudmila R. Zakirova1, Vadim V. Rumbesht1, Galina A. Batischeva2

    Title:Gene polymorphism of CYP2C9 in patients with ischemic heart disease and its significance in the manifestation of genoprotective properties of meldonium
    Journal:Journal of Pharmacy Research
    Vol(issue):11(12)
    Year:2017
    Page No: (1570-1574)
  • Experimental Methods Keywords

    Methodology:Genoprotection, Genotoxicity, Meldonium, Personalized pharmacotherapy, Pharmacogenetics, Polymorphism of the gene CYP2C9*2 C430T
    Research Materials:Patients with ischemic heart disease

Keywords

Genoprotection Genotoxicity Meldonium Personalized pharmacotherapy Pharmacogenetics Polymorphism of the gene CYP2C9*2 C430T

Our Services

Most Downloaded List